Beyond Air Inc (XAIR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Beyond Air Inc stock (XAIR) is currently trading at $0.74. Beyond Air Inc PS ratio (Price-to-Sales) is 1.14. Analyst consensus price target for XAIR is $8.67. WallStSmart rates XAIR as Sell.
- XAIR PE ratio analysis and historical PE chart
- XAIR PS ratio (Price-to-Sales) history and trend
- XAIR intrinsic value — DCF, Graham Number, EPV models
- XAIR stock price prediction 2025 2026 2027 2028 2029 2030
- XAIR fair value vs current price
- XAIR insider transactions and insider buying
- Is XAIR undervalued or overvalued?
- Beyond Air Inc financial analysis — revenue, earnings, cash flow
- XAIR Piotroski F-Score and Altman Z-Score
- XAIR analyst price target and Smart Rating
Beyond Air Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Beyond Air Inc (XAIR) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Beyond Air Inc (XAIR) Key Strengths (3)
Revenue surging 104.70% year-over-year
Paying $1.14 for every $1 of annual revenue
Trading at 1.00x book value, attractively priced
Supporting Valuation Data
Beyond Air Inc (XAIR) Areas to Watch (4)
Company is destroying shareholder value
Losing money on operations
Very low institutional interest at 13.97%
Micro-cap company with very limited liquidity and high volatility
Beyond Air Inc (XAIR) Detailed Analysis Report
Overall Assessment
This company scores 34/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 3 register as strengths (avg 8.7/10) while 4 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Price/Sales, Price/Book. Valuation metrics including Price/Sales (1.14), Price/Book (1.00) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 104.70%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Institutional Own.. Profitability pressure is visible in Return on Equity at -240.20%, Operating Margin at -300.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -240.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 104.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
XAIR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
XAIR's Price-to-Sales ratio of 1.14x trades at a deep discount to its historical average of 165.57x (3th percentile). The current valuation is 100% below its historical high of 1204.62x set in Mar 2023, and 153% above its historical low of 0.45x in Jun 2025. Over the past 12 months, the PS ratio has compressed from ~2.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Beyond Air Inc (XAIR) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Beyond Air Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 7M with 105% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 105% YoY, reaching 7M. This pace significantly outperforms most MEDICAL DEVICES peers.
Spending 35% of revenue (2M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Beyond Air Inc maintain 105%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Beyond Air Inc.
Bottom Line
Beyond Air Inc is a high-conviction growth story with revenue accelerating at 105% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Beyond Air Inc(XAIR)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Beyond Air, Inc., a clinical-stage biopharmaceutical and medical device company, develops nitric oxide (NO) generators and delivery systems. The company is headquartered in Garden City, New York.